Lilly to Acquire AtaiBeckley, Targeting Treatment-Resistant Depression
ATAI has more than doubled off its 52-week low of $2.58.
Summary
Eli Lilly is acquiring AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions, marking Lilly's entry into the psychedelic drug race. The deal is valued at an initial $2.8 billion, with an initial per-share consideration of $6.75. Contingent Value Rights (CVRs) could add up to an additional $1 billion, or $2.75 per share, bringing the total potential deal value to $3.8 billion. This acquisition provides Lilly with a pipeline of novel psychiatric treatments, including AtaiBeckley's BPL-003 program, which recently entered Phase 3, strengthening Lilly's neuroscience portfolio beyond its existing depression drugs. AtaiBeckley had extended its cash runway into 2029, reducing near-term financing risk, and the transaction is subject to customary closing conditions and regulatory approvals.
At the time of this announcement, ATAI was trading at $8.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $2.58 to $6.75. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.